Clinical trials for Dermatomyositis
31 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT07111065FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)National Institute of Environmental Health Sciences (NIEHS) · PI: Lisa G Rider, M.D.
- ACTIVE NOT RECRUITINGNCT07531446Construction of a Clinico-Imaging Collaborative Diagnostic Model for Dermatomyositis Combined With Interstitial Lung Disease Based on PET/CT Imaging Features and Clinical ParametersRuijin Hospital
- RECRUITINGPHASE2, PHASE3NCT07160205Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM)Restem, LLC. · PI: Michael Bubb, MD
- RECRUITINGN/ANCT07377058RCT of Tocilizumab for Anti-MDA5+DMPeking Union Medical College Hospital
- RECRUITINGNCT07345949Panniculitis in DermatomyositisUniversity Hospital, Strasbourg, France
- RECRUITINGPhase 2NCT06857240Topical Ruxolitinib Cream for Refractory Cutaneous DermatomyositisThe Cleveland Clinic · PI: Anthony Fernandez, MD
- RECRUITINGPhase 1NCT06919380Nebulized MSC-Exos for Anti-MDA5+ RP-ILD: Safety and Efficacy TrialLi Shiyue
- RECRUITINGPhase 2NCT06672822Intralesional Injection of STS in Treatment of CalcinosisRobyn T. Domsic, MD, MPH · PI: Robyn T Domsis, MD
- RECRUITINGPhase 3NCT06698796A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory MyopathiesPfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPhase 1NCT06686524Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile Dermatomyositis (RJDM)Chongqing Precision Biotech Co., Ltd
- ACTIVE NOT RECRUITINGPhase 2NCT06284954A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositisargenx
- RECRUITINGPhase 1NCT06298019Study of KYV-101 Anti-CD19 CAR T Therapy in Adult DermatomyositisStanford University · PI: David Fiorentino, MD, PhD
- RECRUITINGPhase 1NCT06569472Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile DermatomyositisChongqing Precision Biotech Co., Ltd · PI: Meiping Lu, M.D
- RECRUITINGPhase 3NCT06455449A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)AstraZeneca
- ENROLLING BY INVITATIONPhase 4NCT064386793T Therapy in the Treatment of MDA5-positive DermatomyositisSecond Affiliated Hospital, School of Medicine, Zhejiang University
- RECRUITINGNCT06203249Microecology and Immunity in Patients With Anti-MDA5 Antibody Positive Dermatomyositis and Interstitial Lung DiseaseChinese PLA General Hospital
- RECRUITINGN/ANCT07037472Photoacoustic/Ultrasound Imaging in Patients of Dermatomyositis With Calcinosis Cutis: Characteristic Findings and Treatment Response EvaluationPeking Union Medical College Hospital
- RECRUITINGNCT06004817Evaluation of Severity in Juvenile and Adult-onset DermatomyositisCentral Hospital, Nancy, France · PI: Paul Decker, MD
- RECRUITINGPhase 3NCT05895786A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]Pfizer · PI: Pfizer CT.gov Call Center
- ACTIVE NOT RECRUITINGPhase 2NCT05695950A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With DermatomyositisGalapagos NV · PI: Galapagos Study Director
- ENROLLING BY INVITATIONPhase 3NCT05495321Interleukin-2 on Active DermatomyositisPeking University People's Hospital · PI: Zhanguo Li
- ACTIVE NOT RECRUITINGPhase 3NCT05437263A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With DermatomyositisPriovant Therapeutics, Inc.
- RECRUITINGPhase 3NCT04972760Baricitinib in Patients With Relapsing or naïve DermatomyositisAssistance Publique - Hôpitaux de Paris · PI: YVES ALLENBACH, MD, PhD
- RECRUITINGNCT07265999Severity Factors of Dermatomyositis in the Caribbean Population - DM-ANTILLESCentre Hospitalier Universitaire de la Guadeloupe · PI: nadège cordel, MD PhD
- RECRUITINGPhase 2NCT03582800Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot StudyUniversity Hospital, Limoges · PI: Vincent GUIGONIS, MD
- ACTIVE NOT RECRUITINGNCT06808672Biomarkers of Cancer-Associated MyositisAzienda USL Reggio Emilia - IRCCS
- RECRUITINGNCT01276470Environmental Risk Factors for the Anti-synthetase SyndromeNational Institute of Environmental Health Sciences (NIEHS) · PI: Adam I Schiffenbauer, M.D.
- RECRUITINGNCT02945345Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)University of Pennsylvania
- RECRUITINGNCT00059748Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile DermatomyositisNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · PI: Hanna Kim, M.D.
- ACTIVE NOT RECRUITINGNCT01171573Investigating Genes in Patients With Polymyositis and DermatomyositisNorthern Care Alliance NHS Foundation Trust · PI: Robert Dr Cooper
- RECRUITINGNCT00017914Adult and Juvenile MyositisNational Institute of Environmental Health Sciences (NIEHS) · PI: Lisa G Rider, M.D.